NASDAQ:ADVM   Adverum Biotechnologies, Inc
ADVM is been a lackluster stock to watch for months. Did a quick fib retracement anyway and as you can see, there's not much volatility here. BUT upcoming events this week could bring some focus to the stock.

The company develops gene therapies with a primary focus on its lead candidate, ADVM-022. Last week, the company presented data from its 2-Year OPTIC study at the Retina Society Annual Meeting. This was specific to treating patients with wet age-related macular degeneration ( AMD ).

Results showed a more than 80% reduction in annualized anti-VEGF injection frequency and a robust response sustained through 2 years. What’s more, this weekend, the company delivered Phase 2 Data from its INFINITY trial targeting patients with diabetic macular edema treated with ADVM-022. Since we likely could see how the market responds once things open on Monday, it could be something to keep in mind with ADVM stock.

What To Watch With ADVM Stock This Week

That isn’t the only thing to keep track of this week, either. Adverum presents results from its Phase 1 OPTIC trial in patients with neovascular AMD treated with ADVM-022. In particular, if ADVM stock is on your list, October 11 will be the day to keep in mind. The company begins its presentation at 9:50 AM ET at the ASRS Scientific Meeting.